Basal cell carcinoma
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Ulcerated maronda anokanganisa ganda remhuno mumunhu akura anowanzoonekwa se Basal cell carcinoma. Mhino inzvimbo yakajairika yekuitika kwerudzi urwu rwegomarara reganda.
Basal cell carcinoma inogona kuuya nemiganhu isina kujairika uye maronda.
Basal cell carcinoma inogona kukanganisa wart.
References
Basal cell carcinoma (BCC) ndiyo yakajairika mhando yegomarara reganda. Kubuda kwezuva ndicho chikonzero chikuru. Anenge ese eBCC makesi anoratidza yakawandisa Hedgehog kusaina mukuongorora kwema molecular. Kurapa kwakasiyana kunowanikwa uye kunosarudzwa zvichienderana nenjodzi yekudzokazve, kukosha kwekuchengetedza matishu, zvinodiwa nemurwere, uye kukura kwechirwere.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas ndidzo mhando dzegomarara reganda muvanhu vakuru vane ganda rakanaka vane makore makumi mashanu zvichikwira. Huwandu hwavo huri kuramba huchikwira pasi rose, kunyanya nekuda kwekusangana nechiedza chezuva. Mamwe genetic mamiriro anogona kuita kuti vanhu vagadzike kuita magomarara aya vachiri vadiki. Basal cell carcinomas zvinosiyana mukuomarara, kubva pazvironda zvinorapika zviri nyore kana kuti nodular kusvika kune zvakakura zvinoda hurukuro muzvikwata zvekurapa zvine hunyanzvi. Prognosis inoenderana nemukana wegomarara kudzoka kana kugona kwayo kukuvadza nyama iri pedyo. Kuvhiya ndiko kurapwa kwakajairwa kwezviitiko zvakawanda, kuve nechokwadi chekubviswa chaiko uye mikana yakaderera yekudzokazve. Nzira shoma dzinopinda dzinogona kurapa maronda epamusoro.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Mushonga wekutanga weBCC kuvhiya. Nokuda kwepamusoro-soro kana kuti inodzokorora BCC, kunyanya munzvimbo dzakaoma, kuvhiyiwa kunoitwa micrographically kunokurudzirwa. Varwere vane ngozi yakaderera-yepamusoro BCC vanogona kufunga nezvekurapa kwepamusoro kana nzira dzinoparadza. Photodynamic therapy inoshanda zvakanaka kune yepamusoro uye yakaderera-njodzi nodular BCCs. Kune yenzvimbo yepamusoro kana metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) inokurudzirwa. Kana paine kufambira mberi kwechirwere kana kusashivirira kune Hedgehog inhibitors, immunotherapy ine anti-PD1 antibody (cemiplimab) inogona kutariswa. Radiotherapy isarudzo yakanaka kune varwere vasingakwanisi kuvhiyiwa, kunyanya varwere vakura. Electrochemotherapy inogona kutariswa kana kuvhiyiwa kana radiotherapy isiri sarudzo.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Zvinhu zvine njodzi zvinosanganisira kuratidzwa kune ultraviolet mwenje, kurapa kwemwaranzi, kuratidzwa kwenguva refu kune arsenic uye kushata immune-system basa (e.g. organ transplantation). Kusangana nemwenje weUV panguva yehudiki kunonyanya kukuvadza.
Mushure mekuongorora ne biopsy, kurapwa kunowanzoitwa nekuvhiyiwa kubviswa. Izvi zvinogona kuitwa nekuchekwa kuri nyore kana kenza iri diki; Kana kenza isiri diki, kuvhiyiwa kweMohs kunowanzo kukurudzirwa.
Basal cell carcinoma inoita 32% yemagomarara pasi rose. Pamagomarara eganda kunze kwemelanoma, angangoita 80% ndeebasal-cell cancers. MuUnited States, inenge 35% yevarume vachena uye 25% yevakadzi vachena vanobatwa nebasal cell carcinoma pane imwe nguva muupenyu hwavo.
○ Kuongororwa uye Kurapwa
#Dermoscopy
#Skin biopsy
#Mohs surgery